

Market Announcement

17 August 2026

Chimeric Therapeutics Limited (ASX: CHM) – Trading Halt

Trading in the securities of Chimeric Therapeutics Limited ('CHM') will be halted at the request of CHM, pending the release of an announcement by CHM.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 19 August 2026; or
- the release of the announcement to the market.

CHM's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance



17 August 2026

ASX Listings Compliance
39 Martin Place
Sydney NSW 2000

Via email

Dear ASX Listings Compliance

Chimeric Therapeutics Limited (ASX: CHM)

Request for trading halt

In accordance with ASX Listing Rule 17.1, Chimeric Therapeutics Limited (ASX: CHM) (the **Company**) requests that its securities be placed into an immediate trading halt pending an announcement in relation to results under the Company's CDH17 Clinical Trial.

The Company requests that trading in its securities be halted until after the expected material announcement is made or until the market opens on Wednesday, 19 August 2026, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information.

Yours sincerely

Nathan Jong
Company Secretary